Abstracts for the upcoming Denver ACS meeting are available on the Division web site. Follow the link below to download the MEDI abstracts for the Boston ACS meeting:


ACS Division of Medicinal Chemistry
Quick Reference Guide to Services
Division Web Site: http://www.acsmedchem.org
Division Hall of Fame:
http://www.acsmedchem.org/hofmain.html
Link to Division Newsletter Archive:
http://www.acsmedchem.org/nl.html
Link to Archived MEDI Meeting Abstracts:
http://www.acsmedchem.org/abstracts.html
Division of Medicinal Chemistry RSS Feed
http://www.acsmedchem.org/acsmedi.rss

ACS Web Page
http://portal.acs.org/portal/acs/corg/content
Journal of Medicinal Chemistry
http://pubs.acs.org/journal/jmcmar

2011 Executive Committee Members
2011 Chair: Jeff Zablocki
2011-2012 Program Chair: Joel Barrish
2011 Vice-Chair: Patrick Woster
Industrial Councillor 2009-11: William J. Greenlee
Industrial Councillor 2010-12: Louis J. Lombardo
Academic Councillor 2011-13: Richard A. Gibbs
Secretary/PR Chair 2011-13: D. Eric Walters
Membership Chair: Yanping Xu
Treasurer 2009-11: Danny Lattin
2011 Past Chair: Laurence Hurley

Contact information for all Division Officers appears at the end of this Newsletter.

Scientific Program for the Denver ACS Meeting
(August 28-September 1, 2011)
(ACS Abstract system now closed for this meeting)

SUN AM  General Oral Session I
SUN AM  siRNA Delivery
SUN PM  First Time Disclosures
SUN PM  General Oral Session II
SUN EVE  Poster Session I and Social Hour
MON AM  Med Chem & Proteins
MON AM  Innovation in the 21st Century
MON PM  Hershberg Award Symposium
MON PM  Medicinal Chemist's Toolbox
MON PM  Antithrombotic Therapy
MON EVE  Sci-Mix
TUES AM  MEDI Awards Symposium
TUES AM  General Oral Session III
TUES PM  Targeting Tumor Stem Cells
TUES PM  GPCR PAMs, NAMs, and SAMs
TUES EVE  MEDI Hall of Fame
WED AM  Drug Discovery Research Centers I
WED AM  Drug Discovery Research Centers II
WED PM  Metabolic Differences in Cancer Cells
WED PM  Huntington's Disease
WED EVE  Poster Session II
THURS AM  General Oral Session IV
THURS AM  Predictive DMPK

Scientific Program for the San Diego ACS Meeting
(March 25-29, 2012)
(ACS Abstract system open in August, 2011)

SUN AM  General Oral Session I
SUN AM  Whole Cell High Throughput Screening
SUN PM  First Time Disclosures
SUN EVE  Poster Session I and Social Hour
MON AM  Alzheimer’s Disease
MON AM  DGAT-1 and Metabolic Diseases
MON PM  CETP Inhibition and Cardiovascular Risk
MON PM  Clearance: Strategies, SAR, Case Studies
TUES AM  Bacterial Resistance I
TUES AM  Desktop Modeling
TUES NOON  Lunch and Learn--Desktop Modeling
TUES PM  Bacterial Resistance II
TUES PM  GPCRs, Structures and Modeling
WED AM  New Chemical/Physicochemical Space
WED PM  GPCR Signaling with Biased Ligands
WED PM  Schizophrenia
WED EVE  Poster Session II
THURS AM  General Oral Session III
THURS AM  Pharma/Academia Collaboration
THURS PM  General Oral Session IV
**Division Travel Grants**

The Division of Medicinal Chemistry makes 14 grants of $600 - $1000 available annually to aid young chemists in presenting papers at the ACS National Meetings. Applicants must be ACS regular or student members, and not have previously received a travel award. Each University department can have only one awardee. Application deadlines are the same as the abstract deadline for each meeting. In order of priority, the following individuals will be considered for awards: Graduate Student, Postdoctoral Fellow, individual with less than five years post-Ph.D. experience. The scientific merit of the paper to be presented will also be considered. Send applications to:

Joel Barrish, Ph.D.  
Bristol-Myers Squibb R&D P.O. Box 4000  
Princeton, NJ 08543  
(609) 252-5897 or (609) 818-5897  
joel.barrish@bms.com

Awardees will be notified in sufficient time so that they can pre-register for the meeting. All travel grant recipients are required to acknowledge the Division in a slide or on their poster as a condition of accepting the award. Awards are made at the Division business meeting, which is held at each national meeting immediately before the Sunday night poster session and mixer. Address info and a complete application appears on page 3.

**Invitation to Authors: Journal of Medicinal Chemistry Perspective Series**

The Perspective series of the *Journal of Medicinal Chemistry* is designed to provide an enlightened appraisal of a field of research in which experts review the state-of-the-art for a given area or therapeutic target. Authors have editorial freedom to express their views on the strategic directions of the field of research. The Perspective series provides a forum with high visibility within the pharmaceutical industry and academia. We would like to identify a wide range of potential topics and authors to ensure that a Perspective article is published in every issue of the Journal. We would like the series to be useful to a broad range of scientists interested in the design, discovery and development of novel medicines. We invite you to submit an idea for a Perspective, along with a brief outline of what you will cover in the manuscript. We also welcome your input regarding potential topics of interest and authors for Perspective manuscripts. Please direct correspondence or calls regarding the series to:

William J. Greenlee  
Schering-Plough Research Institute  
2015 Galloping Hill Road  
Kenilworth, NJ 07033  
Phone (908)-740-2220  
FAX (908)-740-7164  
william.greenlee@merck.com

**CALL FOR PAPERS**

**243rd NATIONAL ACS MEETING**  
San Diego, CA, March 25-29, 2012

The ACS Abstracts System Opens August, 2011

You are invited to submit an abstract for a research presentation at the 243rd National Meeting of the American Chemical Society, to be held March 25-29, 2012 in San Diego, CA. All abstracts should be submitted online using the ACS Abstract system, which will open in August of 2011. The deadline for abstract submission will also be the deadline for submission of travel grant applications, as outlined on page 3 of this Newsletter. Please watch the ACS web site or the Division Homepage, located at:

http://www.acsmedchem.org/

for additional information. The MEDI scientific program and abstracts will be available for download 3-4 weeks prior to the meeting, and their availability will be announced by electronic mail. For more information on programming or abstract submission, contact the Program Chair, Joel Barrish, at joel.barrish@bms.com

**Division Archives Available On-line**

Division newsletters, scientific programs and abstract books dating to 2002 are archived online. These documents can be downloaded in pdf format through the Division WWW page:

http://www.acsmedchem.org
ACS Division of Medicinal Chemistry Student Travel Grants

APPLICANTS MUST SUBMIT AN ABSTRACT SEPARATELY VIA OASYS SYSTEM
The deadline for Travel Grant applications is the same as the abstract deadline for that meeting. All travel grant recipients are required to acknowledge the Division in a slide during oral presentations, or on their poster as a condition of accepting the award.

* Name of Applicant for Travel Grant ____________________________________________

* Degree: ___________________________ Year Obtained ______________________________

* Present Institution: _______________________________________________________________

* Department: ___________________________________________________________________

*E-mail Address: ________________________________________________________________

* Work to be reported was (check one or more):
  a. Ph.D. Thesis __________
  b. M.S. Thesis __________
  c. Postdoctoral Fellowship __________

*Supported by (indicate source of support for this work):
  a. Grant __________________
  b. Department ______________
  c. Other ________________

Send the completed application form and a copy of the OASYS abstract to:

Joel Barrish, Ph.D.
Bristol-Myers Squibb R&D
P.O. Box 4000 Princeton, NJ 08543
(609) 252-5897 or (609) 818-5897
joel.barrish@bms.com
Did I Make What I Think I Made?

Automatically confirm proposed structures based on NMR and LC/UV/MS data.

- Process NMR, LC/UV/MS, IR, Raman and other analytical data from any major instrument, at your desktop
- Confirm proposed chemical structures
- Search and review data in corporate, third-party, and commercial databases to investigate mysterious or unexpected signals
- Effortlessly create reports for paper or electronic lab notebooks

ACS Fall
- Register for our Tuesday AM workshop (Room 503)
- Visit us at Booth 1818

Enquire About Introductory Pricing

www.acdlabs.com/spectrusprocessor
Richard B. Silverman To Receive the E.B. Hershberg Award for Important Discoveries in Medicinally Active Substances

The American Chemical Society Division of Medicinal Chemistry is pleased to announce that Richard B. Silverman, the John Evans Professor of Chemistry at Northwestern University, has been selected as the 2011 recipient of the E.B. Hershberg Award for Important Discoveries in Medicinally Active Substances. The E.B. Hershberg Award was established in 1988 by Schering-Plough Research Institute to honor the contributions of Emanuel B. Hershberg to the pharmaceutical industry, especially the application of organic chemistry for the discovery and development of novel drugs.

Richard B. Silverman received his B.S. degree in chemistry from The Pennsylvania State University in 1968 and his Ph.D. degree in organic chemistry from Harvard University (David H. Dolphin, mentor) in 1974 with time off for a two-year military obligation from 1969-1971. After two years as a NIH postdoctoral fellow in the laboratory of the late Professor Robert H. Abeles in the Graduate Department of Biochemistry at Brandeis University, he joined the chemistry faculty at Northwestern University. In 1986 he became Professor of Chemistry and Professor of Biochemistry, Molecular Biology, and Cell Biology. In 1996 he was named the Arthur Andersen Professor of Chemistry for a period of two years and since 2004 he has been the John Evans Professor of Chemistry. He has supervised 125 graduate students and postdoctoral associates at Northwestern.

Dr. Silverman has published over 275 research papers, holds over 40 patents, and has written four books. He is the inventor of Lyrica® (pregabalin), a blockbuster drug marketed worldwide by Pfizer for refractory epilepsy, neuropathic pain, fibromyalgia, and (in Europe) for generalized anxiety disorder. Awards include: DuPont Young Faculty Fellow (1976), Alfred P. Sloan Research Fellow (1981-1985), NIH Research Career Development Award (1982-1987), Fellow of the American Institute of Chemists (1985), Fellow of the American Association for the Advancement of Science (1990), Arthur C. Cope Senior Scholar Award of the American Chemical Society (2003), Alumni Fellow Award of Pennsylvania State University (2008), and the Perkin Medal from the Society of Chemical Industry (2009). Dr. Silverman will receive the Hershberg Award and present his address at the Fall 2011 ACS meeting in Denver.

46th Midwest/39th Great Lakes Joint Regional ACS Meeting--MWRM/GLRM 2011

Sheraton Westport Chalet
St. Louis, MO
October 19 – 22

Abstract deadline: Wednesday, August 24
http://www.mwrm2011.org/
Connecting Professionals and Students to a Wealth of Pharmaceutical Knowledge…

ACS Medicinal Chemistry Division Members —

Receive 20% off your BOOK purchase.

Just reference promotion code ACSMD when ordering and SAVE 20% off the list price.

Publishing in October 2011!
Development of Therapeutic Agents Handbook
Edited by Shayne Cox Gad
Hardcover • US $245.00
Provides researchers with a thorough reference focusing on applications, practical methods, and techniques to facilitate new drug development.

Publishing in September 2011!
Chiral Drugs: Chemistry and Biological Action
Guo-Qiang Lin, Qi-Dong You, Jie-Fei Cheng
ISBN: 978-0-470-58720-1
US $149.95
Delivers an integrated perspective on chiral drugs from concept, to synthesis, to pharmaceutical properties.

Just Published!
Solid State Characterization of Pharmaceuticals
Edited by Richard A. Storey, Ingvar Ymén
ISBN: 978-1-4051-3494-1
US $239.99
Provides an up-to-date review of the current techniques used to characterize pharmaceutical solids.

Best-Selling!
Basic Pharmacokinetics and Pharmacodynamics: An Integrated Textbook and Computer Simulations
Sara E. Rosenbaum
ISBN: 978-0-470-56906-1
US $59.95
Enables you to grasp all the fundamental concepts of pharmacokinetics and pharmacodynamics and allows you to understand the time course of drug response and dosing regimen design.

Donald J. Abraham & David P. Rotella
ISBN: 978-0-470-27815-4
October 2010
$2350.00
Special price for ACS Medicinal Chemistry Members $2100!

ORDERING INFORMATION
Tel: 877.762.2974
E-mail: custserv@wiley.com
Internet: www.wiley.com

Prefer an e-book? We have those, too! Visit us at ACS Booth #1302 to view our books on your favorite e-readers and find out how you can save!
Journal of Medicinal Chemistry to Transition New Editors

After a dedicated 40 year career as Editor-in-Chief of the *Journal of Medicinal Chemistry*, Dr. Philip S. Portoghese will be retiring from the journal at the end of 2011. Throughout the remainder of the year, the journal will transition two new Editors, Drs. Gunda I. Georg and Shaomeng Wang, who will assume leadership of the journal in January 2012.

“Drs. Georg and Wang are an outstanding choice as the new editors of the journal as both are well-recognized scientists in the field; they will undoubtedly be a magnet for exceptional authors.”

~Philip S. Portoghese

Dr. Georg is department head for the College of Pharmacy's Department of Medicinal Chemistry at the University of Minnesota, where she holds the Robert Vince Endowed Chair and McKnight Presidential Chair and also established and directs the Institute for Therapeutics Discovery and Development. Dr. Georg has published more than 40 peer-reviewed articles and reviews since 2006 and currently holds 7 patents. Her research articles have been published in ACS journals including *Journal of Medicinal Chemistry, The Journal of Organic Chemistry, Journal of the American Chemical Society, Journal of Natural Products, Biochemistry, and Bioconjugate Chemistry*. She currently serves on the Editorial Advisory Board of ACS Medicinal Chemistry Letters and *The Journal of Organic Chemistry*, and previously on the Editorial Advisory Board of the *Journal of Medicinal Chemistry*.

“Under the leadership of Dr. Portoghese, the Journal of Medicinal Chemistry has become the most-cited international journal for the publication of original medicinal chemistry research, this is an extraordinary achievement.”

~Gunda I. Georg

Dr. Wang is the Warner-Lambert/Parke-Davis Professor in Medicine; Professor of Medicine, Pharmacology and Medicinal Chemistry; Co-Director, Molecular Therapeutics Program, and Director, Cancer Drug Discovery Program at the University of Michigan. He has published more than 70 peer-reviewed articles and reviews since 2006 and currently holds 16 patents. His research articles have been published in ACS journals including *Journal of Medicinal Chemistry, ACS Medicinal Chemistry Letters, Journal of the American Chemical Society, Accounts of Chemical Research, Journal of Chemical Information and Modeling, and Biochemistry*. He currently serves as a Senior Editor of the *Journal of Medicinal Chemistry* and on the Editorial Advisory Board of ACS Medicinal Chemistry Letters.

“Dr. Portoghese is a true legend in the field of medicinal chemistry and a visionary in scientific publishing.”

~Shaomeng Wang

Dr. Portoghese will continue to serve as Editor-in-Chief of *Journal of Medicinal Chemistry* until his retirement at the end of the year. Please join us at a reception to honor Dr. Portoghese’s 40 years of service at the ACS Fall National Meeting in Denver, CO:

Saturday, August 27, 2011
7:00 – 9:00 PM
Hyatt Regency Denver, Centennial Ballroom F
Macor, Mitscher, and Silverman Named ACS Fellows

The American Chemical Society Fellows Program recognizes members of ACS for outstanding achievements in and contributions to science, the profession, and society. Three distinguished medicinal chemists are among the 2011 Fellows.

John E. Macor, Executive Director of Neuroscience Discovery Chemistry at Bristol-Myers Squibb earned his B.S. degree from the University of Notre Dame in 1982 and his Ph.D. degree in organic chemistry at Princeton University with Professor E. C. Taylor (1986). He began his career at Pfizer (Groton, CT) in 1986 where he was engaged in a variety of CNS drug discovery efforts, moved to Astra Arcus (Rochester, NY) in 1994 focusing on cholinergic drug discovery, and then moved to Bristol-Myers Squibb in 1997 (Princeton, N.J), starting in cardiovascular and moving to neuroscience in 2001.

Dr. Macor is credited with the discovery of Relpax® (eletriptan), an antimigraine agent with sales of over 500 million dollars annually, and for his central role in the discovery of a number of clinical candidates at Pfizer, Astra and Bristol-Myers Squibb. He discovered CP-93,129, a 5-HT1B receptor selective agonist, and racemic AZD0328, the first brain-penetrant, selective, full agonist for the α7 neuronal nicotinic receptor. At Bristol-Myers Squibb he led the teams that discovered BMS-346567 (a dual AT1/ETA receptor antagonist presently in Phase 2 clinical trials for diabetic neuropathy) and BMS-708163 (a γ-secretase inhibitor for Alzheimer’s Disease).

Dr. Macor has authored or co-authored over 110 publications, and he is an inventor on over 70 issued US patents. Dr. Macor chaired the 2002 Gordon Research Conference on Medicinal Chemistry and the 2006 Gordon Research Conference on Heterocyclic Compounds. He is presently Editor-in-Chief of Annual Reports in Medicinal Chemistry.

Lester A. Mitscher recently retired from the Medicinal Chemistry faculty at the University of Kansas, where he was Chair (1975-1992) and University Distinguished Professor. He is a member of the MEDI Hall of Fame (http://www.acsmedchem.org/mitscher.html). Dr. Mitscher received his Ph. D. degree in Chemistry in 1958 from Wayne State University, Detroit, where he worked under Carl Djerassi. He continued his work on natural product chemistry at Lederle Laboratories from 1958-1967 where he rose to group leader in antibiotic discovery. He accepted an associate professorship in Natural Products Chemistry at The Ohio State University (1967), rising soon to the position of Professor, prior to his move to Kansas. He has published more than 280 research publications and authored or coauthored seven technical books on drug discovery and properties and is on the editorial board of several journals. His research awards include the Smissman Award in Medicinal Chemistry (ACS), Volweiler Award (American Association for Pharmaceutical Education), the Research Achievement Award in Natural Products Chemistry (American Pharmaceutical Association), the Award in Medicinal Chemistry (Medicinal Chemistry Division, ACS), The Norman Farnsworth Research Achievement Award (American Society for Pharmacognosy) and is an Elected Fellow of the American Association for the Advancement of Science and a member of the Medicinal Chemistry Roll of Honor of the American Chemical Society, ACS Medicinal Chemistry Division ACS Hall of Fame, International Union of Pure and Applied Chemistry Emeritus Fellow.

Richard Silverman is featured in another article on page 5 of this Newsletter.
Dale L. Boger To Receive the 2nd Annual Philip S. Portoghese Medicinal Chemistry Lectureship Award, Tuesday, August 30, in Denver (MEDI Awards Symposium)

The American Chemical Society Division of Medicinal Chemistry is pleased to announce that Dale L. Boger, Richard and Alice Cramer Professor of Chemistry, Scripps Research Institute, has been selected as the recipient of the second Philip S. Portoghese Medicinal Chemistry Lectureship. This award is named in honor of Phil Portoghese, the long-standing Editor-in-Chief of the Journal of Medicinal Chemistry. The Lectureship is administered jointly by the Editor-in-Chief of the Journal and the ACS Division of Medicinal Chemistry. The objective of the lectureship is to honor the contributions of an individual who has had a major impact on medicinal chemistry research. The award is funded principally by the Journal of Medicinal Chemistry (ACS Publications Division) and the awardee is selected by a committee appointed jointly by the Journal and the Division of Medicinal Chemistry.

Dr. Boger earned his B.S. in Chemistry at the University of Kansas in 1975. He completed his Ph.D. at Harvard University in 1980. He was a member of the Medicinal Chemistry faculty at the University of Kansas until 1985, and of the Chemistry faculty at Purdue University from 1985 to 1991. He has been a Professor at the Scripps Research Institute since 1991, and a Member of the Skaggs Institute for Chemical Biology since 1996. Dr. Boger has published over 500 research papers and two books. His awards include an Alfred P. Sloan Fellowship, an ACS Arthur C. Cope Scholar Award, the American Cyanamid Academic Award, ISHC Katritzky Award in Heterocyclic Chemistry, ACS Aldrich Award for Creativity in Organic Synthesis, Paul Janssen Prize for Creativity in Organic Synthesis, Adrien Albert Medal of the Royal Society of Chemistry, and ACS Guenther Award in Natural Products. He is a Fellow of the American Association for the Advancement of Science, a Member of the American Academy of Arts and Sciences, a Fellow of the Royal Society of Chemistry, and a Fellow of the American Chemical Society. Dr. Boger is Editor-in-Chief of Bioorganic and Medicinal Chemistry Letters and an Executive Editorial Board Member for Tetrahedron Publications. He has served the ACS Medicinal Chemistry Division as a Councilor and as a member of the Long Range Planning Committee and the Awards Committee.

Bernstein, Burckhalter, Elion, Hess, Johnson, Mertes, Taylor, and Wells to be Inducted into the MEDI Hall of Fame

The Division is pleased to announce that seven medicinal chemists, Peter R. Bernstein, Joseph H. Burckhalter, Gertrude B. Elion, Hans-Jürgen Hess, M. Ross Johnson, Mathias P. Mertes, and James A. Wells, will be inducted into the ACS Division of Medicinal Chemistry Hall of Fame at the Denver ACS meeting. The induction ceremony will be held on Tuesday, August 30, 2011, from 5 - 7 p.m., in the Denver Convention Center, Room 607.

Peter R. Bernstein received a BS in Chemistry with High Distinction from the University of Rochester in 1973, and earned his PhD with Professor Gilbert Stork at Columbia University in 1977. He then served as an Organic Chemistry Fellow in the laboratory of Professor Barry Trost in the Department of Chemistry at the University of Wisconsin, Madison. In 1979, Peter joined the Medicinal Chemistry Department of ICI Pharmaceuticals Group in Wilmington, DE. He worked there 31 years, continuing through its spin-off as Zeneca Pharmaceuticals and through its merger with Astra Pharmaceuticals
to form AstraZeneca Pharmaceuticals. Following his retirement in 2010 he established PhaRmaB LLC as a platform for providing consulting and mentoring in drug discovery and development.

Dr. Bernstein has worked on treatments for many different diseases, and has had more than 10 compounds go into clinical development. He co-invented and helped develop Accolate®, the first leukotriene antagonist to be approved in the US. Next, two inhibitors of human neutrophil elastase entered development. Since then he has worked on or led chemistry teams targeting: neurokinin antagonists, β-estrogen agonists, γ-secretase inhibitors, H3 antagonists, 5-HT1B antagonists and dual NET/DAT reuptake inhibitors. In neurokinin antagonists he led the chemistry teams working on dual NK1/NK2 antagonists for pulmonary disease [ZD6021 and ZD2249] and NK1 antagonists targeted for CNS indications [ZD4974]. Recently, he led the chemistry of, and then was project leader for, the 5-HT1B-antagonist program [AZD3783] and the H3 antagonist program [AZD5213].

Dr. Bernstein is an author on ~190 scientific papers, presentations, and patents.

Joseph H. Burckhalter (1912 - 2004) earned his B.S. in chemistry at the University of South Carolina in 1934, an M.S. in organic chemistry from the University of Illinois in 1938, and his Ph.D. in medicinal chemistry from the University of Michigan in 1942. He worked at Parke-Davis for a number of years, and was instrumental in the discovery of the anti-malarial drugs amodiaquin (Camoquin®) and amopyroquin (Propoquin®). His work also led to two anti-amebic drugs, bialamicol (Camoform®) and clamoxyll. Subsequently he joined the Medicinal Chemistry Department at the University of Kansas, where he initiated the doctoral program in medicinal chemistry. In 1960, he returned to the University of Michigan as Chair of the Medicinal Chemistry Department.

Professor Burckhalter was inducted into the National Inventors Hall of Fame in 1995 for his discovery of fluorescein isothiocyanate (FITC), which is widely used in labelling antibodies. He received the American Innovator Award from the U.S. Patent and Trademark Office, as well as Distinguished Alumni Awards from the University of South Carolina and the University of Illinois.

Gertrude B. Elion (1918-1999) entered Hunter College at the age of 15 and graduated summa cum laude in 1937. She earned her M.S. in chemistry from New York University in 1941. She went to work at Burroughs-Wellcome, where she was inventor or co-inventor of an impressive list of drugs: 6-mercaptopurine (first treatment for leukemia); azathioprine (first immunosuppressive drug); allopurinol (for gout); pyrimethamine (for malaria); trimethoprim (antibacterial); acyclovir (for herpes). She shared the 1988 Nobel Prize in Medicine. The Nobel Prize website includes an autobiography (http://nobelprize.org/nobel_prizes/medicine/laureates/1988/elion.html). She was inducted into the National Inventors Hall of Fame in 1991. Elion was unable to complete her Ph.D. for financial reasons, but during the last thirty years of her life, she was awarded 25 honorary doctorates.

Hans-Jürgen Hess's research interests and expertise range over a wide area of medicinal chemistry, and include cardiovascular drugs, pulmonary/anti-allergy drugs, gastrointestinal drugs, antithrombotic drugs, prostaglandins, cyclic mononucleotide regulation, analgesic drugs, anti-inflammatory drugs, CNS drugs, peptide receptor agonists and antagonists, high throughput screening (HTS), antibiotics, microbial natural product isolation and screening, and structure determination by experimental techniques. He led the discovery efforts leading to pirbuterol (Maxair®), a tissue selective β-adrenergic agonist bronchodilator, sulprostone (Nalador®), a tissue selective prostaglandin analog for obstetric and gynecological uses,
and the first potent, non-peptidic neurokinin-1 (substance P) antagonist. Hans Hess's achievements have been chronicled in about 100 issued US patents and 70 publications and abstracts.

Throughout his scientific career, Hans has been actively involved in professional activities contributing to the advancement of Medicinal Chemistry in numerous ways. For 5 years, from 1979-1983, he was Editor-in-Chief of Annual Reports in Medicinal Chemistry. He served on the Editorial Board of Bioorganic and Medicinal Chemistry Letters, 1991-1996. He was Program Chairman of the Medicinal Chemistry Gordon Research Conference in 1985, and Chairman of the Conference in 1986. He served on Awards Nominating and Long-Range Planning Committees of the Division of Medicinal Chemistry. From 1985-1994, he served on the American Institute of Biological Sciences (AIBS), Army Research and Development Command (AMRDC), Medicinal Chemistry Review Panel.

M. Ross Johnson received his B.S. degree in Chemistry from the University of California at Berkeley in 1967 and a Ph.D. degree in organic chemistry from the University of California at Santa Barbara in 1970. He has over 300 scientific publications, patents, and invited presentations. Dr. Johnson is known for his discovery of nonclassical cannabinoid analgesics exemplified by levonantradol (U.S. Patent 4,486,609), CP-55,940 (U.S. Patent 4,340,737) and CP-55,244 (U.S. Patent 4,306,097). He is also a discoverer and an inventor of record of the ultra short acting analgesic/anesthetic remifentanil /ULTIVA® (U.S. Patent 5,019,583), the oral anti-diabetic englitazone (U.S. Patent 4,739,079), the prostaglandin analog sulprostone/Nalador® (U.S Patent 4,244,887), the use of viral membrane fusion inhibitors such as enfuvirtide (Fuzeon®) in combination with other retroviral drugs (U.S. Patent 6,475,491) to reduce HIV viral load, and the recent discovery of novel epithelial sodium channel blockers such as Parion Sciences 552 and Gilead Sciences 941 (U.S. Patent 6,858,615). These latter agents are being developed for the treatment of cystic fibrosis and chronic bronchitis, the treatment of xerostomia caused by Sjögren’s disease, and as a medical countermeasure therapy to treat victims and protect first responders against threats involving airborne radioactive particles and bioterrorism agents such as anthrax and plague.

Dr. Johnson has served as Chairman of the Organic Chemistry Division of the American Chemical Society and Chairman of the Gordon Research Conference on Natural Products and is a founder of both the International Cannabinoid Study Group and the Glaxo-UNC Frontiers in Chemistry and Medicine Symposia. In 1989, Ross Johnson was named the first “Distinguished Research Fellow” in the Laboratory of Medicinal Chemistry, National Institute of Diabetes, Digestive and Kidney Diseases, National Institutes of Health.

Mathias P. Mertes (1932-1989) received a B.S. degree in pharmacy from the University of Illinois in 1954. Because of a keen interest in research he entered graduate school at the University of Texas, where he received an M.S. degree in medicinal chemistry with C. O. Wilson in 1956. He subsequently earned a Ph.D. degree with Ole Gisvold from the University of Minnesota in 1960. Upon completion of his Ph.D., Matt accepted a position at the University of Kansas as an assistant professor of medicinal chemistry. Matt advanced rapidly in his career, reaching the rank of Professor in 1968 and serving as Chair of the Department of Medicinal Chemistry from 1974-1975.

As a teacher Matt was extremely dedicated, being popular with graduate and undergraduate students alike. He won several teaching awards, including the University of Kansas EXXON Award in 1986 and the Rho Chi Teaching Award presented by students of the School of Pharmacy. As a research scholar Matt's interests varied widely. They included: 1) development of methodology for the synthesis of nucleoside, nucleotide, and nucleic acid analogs, 2) studies on thymidylate synthetase model systems and reaction mechanisms including the design and synthesis of thymidylate synthetase inhibitors, 3) the design, synthesis and evaluation of glutamate receptor probes that discriminate between glutamate receptor subtypes, and 4) with his wife, Kristin, University Distinguished Professor of Chemistry at the University of Kansas, polyammonium macrocycle synthesis,
ligand complexation, and mechanism of catalysis of formyl phosphate and ATP hydrolysis. During his career Matt published over 100 scientific papers and directed 23 graduate students to the Ph.D. degree, in addition to training five M.S. students and a number of postdocs. Matt served as Chair of the Division of Medicinal Chemistry of the American Chemical Society in 1978, as Vice-chair in 1977, and served on the Division’s membership, long-range planning and membership directory committees. He also served on the editorial boards of the Journal of Medicinal Chemistry and Nucleosides and Nucleotides.

Edward C. Taylor received both his B.A. (1946) and his Ph.D. (1949) degrees from Cornell University. He was a Merck Postdoctoral Fellow (1949-50) of the National Academy of Sciences in Zürich, Switzerland, where he studied with Leopold Ruzicka, and then the du Pont Postdoctoral Fellow at the University of Illinois (1950-51). He joined the faculty at the University of Illinois in 1951, and then moved to Princeton University in 1954. In 1966 he was appointed A. Barton Hepburn Professor of Organic Chemistry. He served as Chairman of the Department from 1973 until 1979. He is currently a member of the Board of Editors of Synthetic Communications, Heterocycles, Pteridines, and Advances in Heterocyclic Chemistry. He served as Chairman of the Organic Division of the American Chemical Society in 1976-77.

Other honors include Fulbright, Guggenheim and Alexander von Humboldt awards, the 1974 American Chemical Society Award for Creative Work in Synthetic Organic Chemistry (for his work in organothallium, heterocyclic, pteridine and folate chemistry), the 5th International Award in Heterocyclic Chemistry, the Gowland Hopkins Medal in 1993, and the 1994 Arthur C. Cope Scholar Award of the American Chemical Society. He was the recipient of the 2004 Thomas Alva Edison Award for Invention for his patent on the compound that became Alimta, a new and broadly effective anticancer drug developed and marketed by Eli Lilly and Co, and was selected for the 2006 Heroes of Chemistry Award, together with two scientists from Eli Lilly and Co., and again by the American Chemical Society, for his work on the discovery and development of Alimta “that has led to the welfare and progress of humanity”. By end of 2010, Alimta stood as the most successful new cancer drug, based on sales, in the history of the pharmaceutical industry. He was inducted into the New Jersey Inventors Hall of Fame in 2009, received from the American Chemical Society the Alfred Burger Award in Medicinal Chemistry in March, 2010, and was inducted into the Medicinal Chemistry Hall of Fame of the ACS in 2011.

Prof. Taylor is the author of over 450 scientific papers and 52 U.S. patents on heterocyclic chemistry, organothallium chemistry, natural product chemistry, medicinal chemistry and synthetic methodology.

James A. Wells, Harry Wm. and Diana V. Hind Professor in Pharmaceutical Sciences, University of California, San Francisco, is a leader in the development of new technologies for engineering proteins and for identifying small molecules to aid in drug discovery. He joined UCSF in 2005. He earned a PhD degree in biochemistry from Washington State University with Professor Ralph Yount in 1979 and completed postdoctoral work at Stanford University School of Medicine with Professor George Stark in 1982.

At UCSF, Wells’ research group focuses on the discovery and design of small molecules and enzymes that trigger or modulate cellular processes in inflammation and cancer. Wells’ research spans the multiple disciplines of biophysics, cell biology, molecular biology, biochemistry and chemistry. Wells also directs the Small Molecule Discovery Center (SMDC), which he founded.

Before joining UCSF, Wells was the founding scientist in Genentech’s Protein Engineering Department. He then co-founded Sunesis Pharmaceuticals, where he served as president and chief scientific officer and co-invented a novel drug discovery process, called Tethering, to efficiently screen molecules in search of the most potent compounds to block specific protein action. In 2010
he co-founded Calithera Biosciences, a company focused on the discovery and development of novel small molecule cancer therapeutics through activation of caspases.

Wells is a member of the National Academy of Sciences and a recipient of the Hans Neurath Award by the Protein Society, the Pfizer Award given by the American Chemical Society, the Perlman Lecture Award given by the ACS Biotechnology Division, the du Vigneaud Award given by the American Peptide Society, and the 2010 Merck Award from the ASBMB. Earlier this year, he received the Med Chem Division’s Bristol-Myers Squibb Smissman Award.

Five Students Selected to Receive ACSMEDI Predoctoral Fellowships

The Division of Medicinal Chemistry is pleased to announce that five graduate students have been selected to receive 2010-2011 Predoctoral Fellowships. The awards, consisting of a $26,000 stipend, are granted to predoctoral students in their third or fourth year of graduate study. Winners must be engaged in medicinal chemistry research in a Medicinal Chemistry, Pharmaceutical Chemistry, Biochemistry, or Chemistry department listed in the current ACS Directory of Graduate Research. They must also be U.S. citizens or permanent resident visa holders, and must have at least one year of graduate school remaining as of September, 2010. Two of these awards are supported through the generosity of pharmaceutical companies (as indicated below). Two are supported through the generosity of members of the Division: Richard B. Silverman and Robert Vince have each committed to the sponsorship of Predoctoral Fellowships. The awardees for the 2010-2011 academic year are:

Kara George, University of Pittsburgh (Advisor: Peter Wipf)
Stephanie Kazane, Scripps Research Institute (Advisor: Peter Schultz)
Kareem Khoury, University of Pittsburgh (Advisor: Alexander Dömling)
Matthew O’Reilly, Vanderbilt University (Advisor: Craig Lindsley)
Tyrell Towle, University of Iowa (Advisor: Robert Kerns)

The Division of Medicinal Chemistry would like to thank the sponsors of the Predoctoral Fellowship awards for their generosity and support (Richard B. Silverman, Robert Vince, Amgen, Pfizer, and Sanofi-Aventis), and extend congratulations to the winners.

Call for Papers 43rd Western Regional Meeting (WRM2011)

WRM2011 will be held November 10-12, 2011 in Pasadena CA. Abstracts will be accepted through September 12 and should be submitted online using PACS, the ACS Abstract system, which is now open.

WRM2011 Technical Program Sessions in Biological and Medicinal Chemistry
- Systems Biology
- Peptide Therapeutics: Past, Present and Future
- Biomolecular Engineering and Design of Drug Carriers
- Noninvasive Imaging of Drugs and Other Compounds
- Elucidating Mechanisms for Natural Products Biosynthesis in Multifunctional Enzyme Systems
- Structural Biology at Cell Surfaces
- Protein Engineering

http://www.wrmacs.org/
A peer-reviewed journal publishing medicinal chemistry research, including new studies related to biologically-active chemical or biochemical entities that can act as pharmacological agents with therapeutic potential or relevance.

*MedChemComm* is a monthly journal containing a mix of vibrant and concise research and review articles. It complements the existing RSC Publishing portfolio of bioscience journals, providing authors in the field with a dedicated subject-specific publication.

For free online access to *MedChemComm* during 2011 sign up for a personal account at www.rsc.org/personalregistration

Co-Editor-in-Chief: Dr Anthony Wood, Pfizer, UK

Co-Editor-in-Chief: Professor Greg Verdine, Harvard University, USA

Sign up for free access today!
Division News in RSS Format

ACSMEDI news and announcements are now posted periodically on the Division RSS feed. RSS (Really Simple Syndication) continually delivers the latest news directly to your reader (also known as a News Aggregator). RSS feeds have an URL just like a web page, except that they end in .rss or .xml. They are marked on most web pages with a red logo that either says XML or RSS. Most web browsers now have seamless support for RSS, and the list for each of your subscriptions is updated automatically. When you visit a web page, click on the red icon to get the RSS address. **Members are encouraged to utilize this technology to receive Division news. This will help us minimize the number of emails sent out by the Division.** For more information on using the Division RSS feed, go to: http://www.acsmedchem.org

and click on the red RSS link to access the feed. You may direct all questions to the Division webmaster.

Advertise in the ACSMEDI Newsletter

The ACSMEDI Newsletter is distributed twice a year to 10,500 medicinal and organic chemist members, and is freely accessible to all through the ACSMEDI homepage. In response to a number of inquiries, we have established the following advertising policy:

<table>
<thead>
<tr>
<th>Size</th>
<th>Cost</th>
</tr>
</thead>
<tbody>
<tr>
<td>One-quarter</td>
<td>$350.00</td>
</tr>
<tr>
<td>One-half</td>
<td>$500.00</td>
</tr>
<tr>
<td>Full page</td>
<td>$900.00</td>
</tr>
</tbody>
</table>

To place an ad or obtain more information, contact the editor at eric.walters@rosalindfranklin.edu

Sponsorship for Division of Medicinal Chemistry Symposia

Division of Medicinal Chemistry symposia at National Meetings are presented in part through the financial support of sponsor companies. Sponsorship opportunities are available for all upcoming Division of Medicinal Chemistry Symposia. Symposium sponsors for national ACS meetings are acknowledged with a prominent sign outside the meeting room, and by session chairs during the symposium. In addition, a table is provided where company representatives can interact with meeting attendees, and provide promotional materials. For more information on symposium sponsorship, contact the Program Chair, Joel Barrish (joel.barrish@bms.com), or the Division Chair, Jeff Zablocki (jeff.zablocki@gilead.com).
1. Regular Executive Committee Members

Chair 2011
Jeff Zablocki, Ph.D.
Gilead, Inc.
3172 Porter Drive
Palo Alto, CA 94304
(650) 384-8547
jeff.zablocki@gilead.com

Treasurer 2009-2011
Danny L. Lattin, Ph.D.
643 Massachusetts, Suite 200
Lawrence, KS 66047
(785) 843-3460
lattind@ku.edu

Vice Chair 2011
Patrick M. Woster, Ph.D.
Department of Pharmaceutical and Biomedical Sciences
Medical University of South Carolina
280 Calhoun Street
QF410, MSC 140
Charleston, SC 29425
(893) 792-2719
woster@musc.edu

Academic Councilor 2011-2013
Richard A. Gibbs, Ph.D.
Department of Medicinal Chemistry and Molecular Pharmacology
575 Stadium Mall Drive
Purdue University
West Lafayette, IN 47907-2091
(765) 494-1456
rag@pharmacy.purdue.edu

Program Chair 2011-2012
Joel Barrish, Ph.D.
Bristol-Myers Squibb R&D
P.O. Box 4000
Princeton, NJ 08543
(609) 252-5897 or (609) 818-5897
joel.barrish@bms.com

Academic Councilor 2009-2011
Wendel L. Nelson, Ph.D.
Department of Medicinal Chemistry
College of Pharmacy
University of Washington
Seattle, WA, 98195-7610
(206) 543-2209
wlnelson@u.washington.edu

Secretary and Public Relations 2011-2013
D. Eric Walters, Ph.D.
Rosalind Franklin University
3333 Green Bay Rd
North Chicago, IL 60064
(847)578-8613
eric.walters@rosalindfranklin.edu

Industrial Councilor 2009-2011
William Greenlee, Ph.D.
Merck Research Laboratories
K15-4
2015 Galloping Hill Road
Kenilworth, NJ 07033,
(908) 740-2220
william.greenlee@merck.com

Membership Chair
Yanping Xu, Ph.D.
Lilly Research Laboratories
Lilly Corporate Center
DC1910
Indianapolis, IN 46285
(317) 433-1113
xu_yanping@lilly.com

Industrial Councilor 2010-2012
Louis J. Lombardo, Ph.D.
Bristol-Myers Squibb Research and Development
Princeton, NJ 08543-4000
609-252-4265
louis.lombardo@bms.com
Past Chair 2011
Laurence Hurley, Ph.D.
Keating Bioresearch Building 102
1657 E. Helen St.
University of Arizona
Tucson, AZ 85721
(520) 626-5622
hurley@pharmacy.arizona.edu

2. Alternate Councilors and Members-at-Large (Ad Hoc EC Members)

Academic Alternate Councilor 2011-2013
Shelli McAlpine, Ph.D.
Dept of Chemistry and Biochemistry
CSL 208
5500 Campanile Dr.
San Diego State University
San Diego, CA  92182
(619)594-5595
mcalpine@chemistry.sdsu.edu

Academic Alternate Councilor 2009-2011
Thomas E. Prisinzano, Ph.D.
Dept. of Medicinal Chemistry
1251 Wescoe Hall Drive
4070 Malott Hall
Lawrence, Kansas 66045-7582
(785) 864-3267
prisinza@ku.edu

Industrial Alternate Councilor 2009-2011
Peter R. Bernstein, Ph.D.
Department of Chemistry
AstraZeneca Pharmaceuticals
1800 Concord Pike
Wilmington, DE 19803
(302) 886-8966
bernstein9@aol.com

Journal of Medicinal Chemistry Liaison 2011
Yusuf J. Abul-Hajj Department of Medicinal
Chemistry Senior Editor, *Journal of Medicinal
Chemistry* 308 Harvard Street SE
College of Pharmacy University of
Minnesota Minneapolis, MN 55455
(612)-624-5987 abulh001@umn.edu

Editor-in-Chief, *Annual Reports in
Medicinal Chemistry* (2007-2011)
John E. Macor, Ph.D.
Executive Director, Neuroscience
Discovery Chemistry
Bristol-Myers Squibb
5 Research Parkway
Wallingford, CT 06492
(203) 677-7092
john.macor@bms.com

Industrial Alternate Councilor 2010-2012
Yao-Chang Xu, Ph.D.
Novartis Pharmaceuticals
No. 8 Building, Lane 898 Helei Road
Zhangjiang Hi-Tech Park, Pudong
Shanghai, 201203, China
+86 21 6160 6359
yao-chang.xu@novartis.com

Foreign Societies Liaison 2011
Thomas J. Perun, Ph.D.
47731 Old Houston Hwy
Hempstead, TX 77445
tjperun@aol.com
Patrick M. Woster, Ph.D. (Chair)
3132 Applebaum Hall
Wayne State University
Detroit, MI 48202
(313) 577-1523
pwoster@wayne.edu

Robert J. DeVita, Ph.D. (2010-2012)
Director, Medicinal Chemistry
Merck Research Laboratories
PO Box 2000, RY121E-22
Rahway, NJ 07065-0900
(732) 594-7039
robert_devita@merck.com

Shelly McAlpine, Ph.D. (2010-2012)
Dept. of Chemistry and Biochemistry
Molecular Biology Institute
5500 Campanile Road, 208 CSL
San Diego State University
San Diego, CA 92182-1030
(619) 993-8609
mcalpine@chemistry.sdsu.edu

John Butera, Ph.D. (2010-2012)
Jbuttera1027@gmail.com

Carole A. Bewley, Ph.D. (2009-2011)
Laboratory of Bioorganic Chemistry, Senior Investigator
NIDDK, National Institutes of Health
8 Center Drive, Room 1A-02
Baltimore, MD 20892-0820
Phone: 301-594-5187
caroleb@mail.nih.gov

Donald L. Hertzog, Ph.D. (2009-2011)
GlaxoSmithKline
Five Moore Drive
Research Triangle Park, NC 27707
(919) 483-5892
donald.l.hertzog@gsk.com

Tom Bannister, Ph.D. (2009-2011)
Associate Scientific Director
Medicinal Chemistry & Translational Research
Scripps Research Institute, Florida Campus
130 Scripps Way #2A1
Jupiter, FL 33458
(561) 228-2206
tbannist@scripps.edu

Jean Chmielewski, Ph.D. (2010-2012)
Department of Chemistry
560 Oval Drive
Purdue University
West Lafayette, IN 47907
Voice: 765-494-0135
FAX: 765-494-0239
chml@purdue.edu

Wendy B. Young, Ph.D. (2010-2012)
Genentech, Inc.
1 DNA Way
South San Francisco, CA 94080-4990
Voice: (650) 467-7945
FAX: (650) 866-6655
young.wendy@gene.com

Katherine L. Seley-Radtke, Ph.D. (2010-2012)
Dept of Chemistry and Biochemistry
Univ of Maryland Baltimore County
1000 Hilltop Circle
Baltimore, MD 21250-0001
Voice: (410) 455-8684
FAX: (410) 455-2608
kseley@umbc.edu

Thomas S. Scanlan, Ph.D. (2009-2011)
Dept of Physiology & Pharmacology
Oregon Health & Science University
3181 SW Sam Jackson Park Rd
Portland, OR 97239
(503) 494-9292
scanlant@ohsu.edu
Amy Ripka, Ph.D. (2011-2013)
EnVivo Pharmaceuticals 480 Arsenal Street
Watertown, MA 02472
(617) 225-4229
aripka@envivopharma.com

Lauren Monovich (2011-2013)
Novartis Institutes for BioMedical Research
USCA, 601-3209
100 Technology Square
Cambridge, MA 02139
(617) 871-7606
lauren.monovich@novartis.com

Nick Meanwell (2011-2013)
Bristol-Myers Squibb
5 Research Parkway
Wallingford, CT 06492
(203) 677-6679
nicholas.meanwell@bms.com

Carrie Haskell-Luevano (2011-2013)
University of Florida College of Pharmacy Department of Pharmacodynamics
1600 SW Archer Rd, Rm P1-20
PO Box 100487
Gainesville, FL 32610-0487
(352) 273-7717
carrie@cop.ufl.edu